Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Clinical trial NCT03712930 · TERMINATED

Trial details

NCT number: NCT03712930
Sponsor: BeiGene
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)

Start date: 2019-02-05
Primary completion: 2020-08-06
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.